or
forgot password

Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer


Inclusion Criteria:



- Advanced cancer excluding cancer within the blood, adequate kidney and liver
function.

Exclusion Criteria:

- Prior use of vinflunine, other active medical disorders, severe nerve damage

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the effect of ketoconazole on the pharmacokinetics of vinflunine in patient with advanced cancer. A total of 28 blood samples will be collected

Outcome Time Frame:

Days 1 through 5 and Day 8 of Cycles 1 and 2

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA183-009

NCT ID:

NCT00388557

Start Date:

October 2005

Completion Date:

September 2007

Related Keywords:

  • Cancer

Name

Location

Tennessee Oncology, PLLC Clarksville, Tennessee  37043